P438: Efficacy and safety of ustekinumab for Ulcerative Colitis through 4 years in Asian patients: Final results from the sub-population of UNIFI long-term extensionECCO’23 CopenhagenYear: 2023
Authors: Hisamatsu, T.(1)*;Kim, H.J.(2);Motoya, S.(3);Suzuki, Y.(4);Ohnishi, Y.(5);Marano, C.(6);Imai, Y.(7);Saadoun, C.(8);Zhuo, J.(9);Kawamura, S.(8);
(1)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(2)Kyung Hee University College of Medicine, Center for Crohn's and Colitis- Department of Gastroenterology, Seoul, Korea- Republic Of;(3)Sapporo-Kosei General Hospital, IBD Center- Hokkaido Prefectural Welfare Federation of Agricultural Cooperative, Hokkaido, Japan;(4)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine-, Sakura, Japan;(5)Shizuoka Medical Center, Division of Gastroenterology, Shizuoka, Japan;(6)Janssen Research & Development- LLC, Immunology, Spring House, United States;(7)Janssen Pharmaceuticals K.K. Japan, Immunology, Tokyo, Japan;(8)Janssen Pharmaceuticals Asia Pacific, Immunology, Singapore, Singapore;(9)Janssen China Research & Development, Biostatistics, Shanghai, China;UNIFI Investigators
P439: Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Panés, J.(1)*;Louis, E.(2);Bossuyt, P.(3);Joshi, N.(4);Lee, W.J.(4);Lacerda, A.(4);Remple, V.(4);Xuan, S.(4);Loftus Jr. , E.V.(5);
(1)Hospital Clinic Barcelona- IDIPABS- CIBERehd, n/a, Barcelona, Spain;(2)University Hospital CHU of Liège, n/a, Liège, Belgium;(3)Imelda General Hospital, n/a, Bonheiden, Belgium;(4)AbbVie Inc., n/a, Chicago, United States;(5)Mayo Clinic College of Medicine and Science, n/a, Rochester, United States;
P440: Prevalence of NUDT15 polymorphisms and incidence of thiopurine-induced leukopenia in Inflammatory Bowel Disease patients: A systematic review and meta-analysisECCO’23 CopenhagenYear: 2023
Authors: Yu, N.(1);Sriranganathan, D.(2);Walker, G.J.(3);Sazonovs, A.(4);Wilding, H.(5);Kennedy, N.A.(6,7);Ahmad, T.(6,7);Boyapati, R.K.(8,9);Segal, J.P.(10,11);Ding, N.J.S.(1,11)*;
(1)St Vincent's Hospital Melbourne, Gastroenterology, Melbourne, Australia;(2)Whipps Cross University Hospital, Gastroenterology, London, United Kingdom;(3)Torbay and South Devon NHS Foundation Trust, Gastroenterology, Torquay, United Kingdom;(4)Wellcome Sanger Institute, Genomics of Inflammation and Immunity Group, Hinxton, United Kingdom;(5)St Vincent's Hospital Melbourne, Library Service, Melbourne, Australia;(6)Royal Devon and Exeter Hospital NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(7)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(8)Monash Health, Gastroenterology, Melbourne, Australia;(9)Monash University, Medicine, Melbourne, Australia;(10)Northern Hospital, Gastroenterology, Melbourne, Australia;(11)The University of Melbourne, Medicine, Melbourne, Australia;
P441: Long-term CD treatment failure and dose modification rates with vedolizumab and other biologics: Results from a large prospective observational studyECCO’23 CopenhagenYear: 2023
Authors: Siegmund, B.(1)*;Siegel, C.A.(2);Sebastian, S.(3);Zhou, J.(4);Jones, S.(5);Adsul, S.(4);Louis, E.(6);
(1)Charité – Universitätsmedizin Berlin- Campus Benjamin Franklin, Medical Department- Division of Gastroenterology- Infectiology and Rheumatology-, Berlin, Germany;(2)Dartmouth Hitchcock Medical Center, Gastroenterology and Hepatology, Lebanon- NH, United States;(3)Hull University Teaching Hospital, IBD Unit, Hull, United Kingdom;(4)Takeda, Gastroenterology, Cambridge- MA, United States;(5)Takeda, Gastroenterology, Zurich, Switzerland;(6)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;
P442: Endoscopic resection of visible precancerous lesions in patients with colonic Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Busacca, A.(1)*;De Sire, R.(1);Capogreco, A.(1);Dal Buono, A.(2);Gabbiadini, R.(2);Loy, L.(2);Finati, E.(1);Spadaccini, M.(1);Maselli, R.(1);Hassan, C.(1);Repici, A.(1);Armuzzi, A.(2);
(1)IRCCS Humanitas Research Hospital, Endoscopy Unit- Department of Gastroenterology, Rozzano, Italy;(2)IRCCS Humanitas Research Hospital, IBD Unit- Department of Gastroenterology, Rozzano, Italy;
P443: Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort StudyECCO’23 CopenhagenYear: 2023
Authors: Le Cosquer, G.(1);Gilletta, C.(1);Amiot, A.(2);Rivière, P.(3);Nachury, M.(4);Rouillon, C.(5);Bouhnik, Y.(6);Abitbol, V.(7);Nancey, S.(8);Fumery, M.(9);Savoye, G.(10);Biron , A.(11);Picon, L.(12);Peyrin-Biroulet, L.(13);Vidon, M.(14);Reenaers, C.(15);Simon, M.(16);Caron, B.(13);Serrero , M.(17);Altwegg, R.(18);Benezech, A.(19);Goutorbe, F.(20);Rahier, J.F.(21);Beaugerie, L.(22);Pelletier, A.L.(23);Caillo, L.(24);Laharie, D.(3)*;Poullenot, F.(3);
(1)Toulouse Rangueil University Hospital, Department of Gastroenterology and Pancreatology, Toulouse, France;(2)Hôpital Bicêtre, Department of Gastroenterology, Le Kremlin Bicêtre, France;(3)CHU de Bordeaux, Service d'Hépato-gastroentérologie et oncologie digestive, Bordeaux, France;(4)Lille University Hospital, Department of Gastroenterology and Hepatology, Lille, France;(5)Caen University Hospital, Hepato-gastroenterology Department, Caen, France;(6)Beaujon Hospital, Department of Gastroenterology, Clichy, France;(7)Hôpital Cochin, Department of Gastroenterology, Paris, France;(8)Lyon University Hospital, Department of Gastroenterology, Lyon, France;(9)Amiens University Hospital, Department of Gastroenterology, Amiens, France;(10)Rouen University Hospital-Charles Nicolle, Department of Gastroenterology, Rouen, France;(11)Reims University Hospital, Department of Gastroenterology, Reims, France;(12)Tours University Hospital, Department of Gastroenterology, Tours, France;(13)Nancy University Hospital, Department of Gastroenterology, Nancy, France;(14)Hôpital Intercommunal de Créteil, Department of Gastroenterology, Créteil, France;(15)CHU Sart Tilman, Department of Gastroenterology, Liège, Belgium;(16)Institut Mutualiste Montsouris, Department of Gastroenterology, Paris, France;(17)APHM Hôpital Nord, Department of Gastroenterology, Marseille, France;(18)Saint-Eloi Hospital, Department of Gastroenterology, Montpellier, France;(19)Henri Duffaut Hospital, Department of Gastroenterology, Avignon, France;(20)Cote Basque Hospital, Department of Gastroenterology and Hepatology, Bayonne, France;(21)Centre Hospitalier Universitaire Université Catholique de Louvain Namur, Department of Gastroenterology, Yvoir, Belgium;(22)Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France;(23)Bichat Hospital, Department of Gastroenterology, Paris, France;(24)Nimes University Hospital, Department of Gastroenterology, Nimes, France;
P444: A systematic literature review (SLR) of real-world studies of advanced therapies in moderate-to-severe ulcerative colitis (UC): study, patient and clinical characteristics, and outcomes assessedECCO’23 CopenhagenYear: 2023
Authors: Irving, P.M.(1);Hur, P.(2)*;Gautam, R.(3);Guo, X.(4);Vermeire, S.(5);
(1)Guy's and St Thomas' Hospital- Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(2)Pfizer Inc, HEOR - Inflammation and Immunology, New York, United States;(3)EVERSANA Pvt. Ltd., HEOR/Real-World Evidence, Mumbai, India;(4)Pfizer Inc, Gastroenterology- Inflammation and Immunology, Collegeville- PA, United States;(5)University Hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;
P445: Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn's Disease and Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Peyrin-Biroulet, L.(1);Bossuyt, P.(2);Bettenworth, D.(3);Loftus Jr., E.V.(4);Anjie, S.(5);D'Haens, G.(5);Saruta, M.(6);Arkkila, P.(7);Kim, D.H.(8);Choi, D.(8);Reinisch, W.(9)*;
(1)Centre Hospitalier Régional Universitaire de Nancy, Department of Gastroenterology, Nancy, France;(2)Imelda GI Clinical Research Centre, Imelda General Hospital, Bonheiden, Belgium;(3)University of Münster, Medical Faculty, Münster, Germany;(4)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;(5)Amsterdam UMC University of Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(6)The Jikei University School of Medicine, Department of Internal Medicine, Tokyo, Japan;(7)Helsinki University Hospital, Department of Gastroenterology, Helsinki, Finland;(8)Celltrion Healthcare Co., Ltd, Incheon, Korea- Republic Of;(9)Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria;
P446: The INTESTINE study: INtended TEmporary STomas In crohN's diseasEECCO’23 CopenhagenYear: 2023
Authors: Perrott, C.(1)*;Calini, G.(2);Gori, A.(3);Rottoli, M.(3);Garoufalia, Z.(4);Wexner, S.(4);Celentano, V.(1);
(1)Chelsea & Westminster Hospital, General Surgery, London, United Kingdom;(2)University of Udine, General Surgery, Udine, Italy;(3)Alma Mater Studiorum University of Bologna, Department of Medical and Surgical Sciences, Bologna, Italy;(4)Cleveland Clinic Florida, Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Weston, United States;The INTESTINE Study Group
P447: Early predictors of the need for surgery in patients with acute severe ulcerative colitis: results of the prospective, observational, international ESCP MASC studyECCO’23 CopenhagenYear: 2023
Authors: Frasson, M.(1);Pinkney, T.(2);Gisbert, J.P.(3);Rodriguez-Lago, I.(4);Blackwell, S.(5);Gecse, K.B.(6);Buskens , C.J.(7);Knowles, C.(8);Zmora, O.(9);Brookes, M.(10);Fiorino, G.(11);Nos, P.(12);Gallo, G.(13);Pata, F.(14);Verjee, A.(15);Leone, S.(16);PellinoMD- PhD- FRCS- FEBS Colo- FASCRS- FACS, G.(17)*;
(1)Hospital La Fe Valencia, Colorectal Surgery, Valencia, Spain;(2)Queen Elizabeth Hospital- University of Birmingham, Academic Department of Surgery, Birmingham, United Kingdom;(3)- Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid UAM, Gastroenterology Unit, Madrid, Spain;(4)Hospital Universitario de Galdakao- Biocruces Bizkaia Health Research Institute, Gastroenterology Department, Galdakao, Spain;(5)Patient representative, Patient representative, Liverpool, United Kingdom;(6)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)Amsterdam UMC, Department of Surgery, Amsterdam, The Netherlands;(8)Queen Mary University of London, Blizard Institute Knowles- Centre for Neuroscience- Surgery & Trauma, London, United Kingdom;(9)Assaf Harofeh Medical Center, Division of General Surger, Zerifin, Israel;(10)Royal Wolverhampton NHS Trust, Department of Gastroenterology, Wolverhampton, United Kingdom;(11)IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Department of Gastroenterology and Digestive Endoscopy, Milan, Italy;(12)La Fe University Hospital, Department of Gastroenterology, Valencia, Spain;(13)Sapienza University of Rome, Department of Surgical Sciences-, Rome, Italy;(14)Nicola Giannettasio Hospital, General Surgery Unit, Corigliano-Rossano, Italy;(15)Patient representative, Patient representative, London, United Kingdom;(16)AMICI Italia Onlus, Patient representative, Milan, Italy;(17)Università degli Studi della Campania "Luigi Vanvitelli", Department of Advanced Medical and Surgical Sciences, Naples, Italy;on behalf of the MASC Study Collaborators
P448: Long term effectiveness of first-line infliximab treatment compared to conventional treatment in paediatric moderate-to-severe Crohn's disease – an update from the TISKids studyECCO’23 CopenhagenYear: 2023
Authors: Vuijk, S.(1)*;Jongsma, M.(1);Cozijnsen, M.(1);van Pieterson, M.(1);de Meij, T.(2);Norbruis, O.(3);Groeneweg, M.(4);Wolters, V.(5);van Wering, H.(6);Hojsak, I.(7);Kolho, K.L.(8);Hummel, T.(9);Stapelbroek, J.(10);van der Feen, C.(11);van Rheenen, P.(12);van Wijk, M.(2);Teklenburg, S.(3);Escher, J.(1);de Ridder, L.(1);
(1)Erasmus Medical Center / Sophia Children's Hospital, Department of Paediatric Gastroenterology, Rotterdam, The Netherlands;(2)Emma Children's Hospital- Amsterdam UMC- VU University, Department of Paediatric Gastroenterology, Amsterdam, The Netherlands;(3)Isala Hospital, Department of Paediatric Gastroenterology, Zwolle, The Netherlands;(4)Maasstad Hospital, Department of Paediatric Gastroenterology, Rotterdam, The Netherlands;(5)Utrecht Medical Center/ Wilhelmina Children's Hospital, Department of Paediatric Gastroenterology, Utrecht, The Netherlands;(6)Amphia Hospital, Department of Paediatric Gastroenterology, Breda, The Netherlands;(7)Children's Hospital Zagreb, Department of Paediatric Gastroenterology, Zagreb, Croatia;(8)University of Helsinki, Department of Pediatric Gastroenterology, Helsinki, Finland;(9)Medical Spectrum Twente, Department of Paediatric Gastroenterology, Enschede, The Netherlands;(10)Catharina Hospital, Department of Paediatric Gastroenterology, Eindhoven, The Netherlands;(11)Jeroen Bosch Hospital, Department of Paediatric Gastroenterology, ‘s Hertogenbosch, The Netherlands;(12)University of Groningen- University Medical Center, Department of Paediatric Gastroenterology, Groningen, The Netherlands;
P450: Real life Effectiveness and safety of an induction treatment with tofacitinib in patients with Ulcerative Colitis: First results of the French TOFAST cohortECCO’23 CopenhagenYear: 2023
Authors: Fumery, M.(1)*;Bouhnik, Y.(2);Faure, P.(3);Bouzidi, A.(4);Brault, Y.(5);Peyrin-Biroulet, L.(6);Laharie, D.(7);
(1)CHU Amiens, Gastroenterology and Hepatology, Amiens, France;(2)Groupe hospitalier Ambroise Paré - Hartmann, Institut des MICI, Neuilly sur Seine, France;(3)Clinique Pasteur, Hepatology and gastroenterology, Tououse, France;(4)Pfizer, Infammation & Immunology, Paris, France;(5)Pfizer, Inflammation & Immunology, Paris, France;(6)University Hospital, Gastroenterology, Nancy, France;(7)Hepatology and Gastroenterology, CHU Bordeaux, Bordeaux, France;
P451: Early infliximab trough levels in paediatric IBD patients predict sustained remissionECCO’23 CopenhagenYear: 2023
Authors: BeversMD, N.(1)*;Aliu, A.(2);Wong, D.(3);Derijks, L.(4);Winkens, B.(5);Vreugdenhil, A.(6);Pierik, M.(7);van Rheenen, P.(8);
(1)Zuyderland Medical Centre, Department of Paediatrics, Heerlen, The Netherlands;(2)Maastricht University, Department of internal medicine- division of Gastroenterology and Hepatology- School for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht, The Netherlands;(3)Zuyderland Medical Center, Department of Clinical pharmacy- Pharmacology and Toxicology, Sittard, The Netherlands;(4)Maxima Medical Centre, Department of Clinical pharmacy, Veldhoven, The Netherlands;(5)Maastricht University, Department of Methodology and Statistics- Care and Public Health Research Institute CAPHRI, Maastricht, The Netherlands;(6)Maastricht University Medical Centre, Department of Paediatrics and NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands;(7)Maastricht University Medical Center, Department of Internal Medicine- Division of Gastro-enterology and Hepatology-School for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht, The Netherlands;(8)University of Groningen- University Medical Centre Groningen - Beatrix Children's Hospital, Department of Paediatric Gastroenterology Hepatology and Nutrition, Groningen, The Netherlands;
P452: Fecal Microbiota Transplantation Leads to Lower IBD Related Complications in Hospitalized Inflammatory Bowel Disease Patients with Clostridioides difficile Infection: A retrospective cohort studyECCO’23 CopenhagenYear: 2023
Authors: Le, P.H.(1)*;Chiu, C.H.(2);Chiu, C.T.(1);Kuo, C.J.(1);Yeh, P.J.(3);Chen, C.C.(3);Pan, Y.B.(4);
(1)Chang Gung Memorial Hospital- Linkou Branch, Department of Gastroenterology and Hepatology, Taoyuan, Taiwan;(2)Chang Gung Memorial Hospital, Chang Gung Microbiota Therapy Center, Taoyuan, Taiwan;(3)Chang Gung Memorial Hospital- Linkou Branch, Department of Pediatric Gastroenterology, Taoyuan, Taiwan;(4)Chang Gung Memorial Hospital- Linkou Branch, Biostatistical Section- Clinical Trial Center, Taoyuan, Taiwan;
P453: The significance of the concentration of antibodies to infliximab on the frequency of loss of response when alternating the original drug infliximab and its biosimilar in patients with ulcerative colitis.ECCO’23 CopenhagenYear: 2023
Authors: Zviaglova, M.(1)*;Knyazev, O.(1);Kagramanova, A.(1);Lischinskaya, A.(1);Podolskaya, D.(2);Nanaeva, B.(2);
(1)Moscow Clinical Scientific Center named after A. S. Loginov, Department of IBD, Moscow, Russian Federation;(2)National Medical Research Сenter of Coloproctology named after A. N. Ryzhykh, Department of IBD, Moscow, Russian Federation;
P454: No increased postoperative risk of venous thromboembolism nor infectious complications after JAK inhibitor exposure in patients with ulcerative colitis undergoing colectomyECCO’23 CopenhagenYear: 2023
Authors: De Greef, I.(1)*;Bislenghi, G.(2);Terrasson, I.(2);Sabino, J.(1);Ferrante, M.(1);D'Hoore, A.(2);Vermeire, S.(1);Verstockt, B.(1);
(1)KU Leuven, Department of Chronic Diseases- Metabolism and Ageing CHROMETA, Leuven, Belgium;(2)University hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium;
P455: Comparison of two strategies for the management of post-operative recurrence in Crohn's disease patients with one clinical risk factor: a multicentre IG-IBD studyECCO’23 CopenhagenYear: 2023
Authors: Dragoni, G.(1)*;Castiglione, F.(2);Bezzio, C.(3);Pugliese, D.(4);Spagnuolo, R.(5);Viola, A.(6);Cocomazzi, F.(7);Aratari, A.(8);Savarino, E.V.(9);Balestrieri, P.(10);Onali, S.(11);Viganò, C.(12);Ribaldone, D.G.(13);Innocenti, T.(14);Testa, A.(2);Saibeni, S.(3);Privitera, G.(4);Milla, M.(14);Armuzzi, A.(15);Fantini, M.C.(11);Fiorino, G.(16);
(1)Careggi University Hospital, Department of Gastroenterology, Firenze, Italy;(2)AOU Federico II Napoli, Gastroenterology- Department of Clinical Medicine and Surgery, Naples, Italy;(3)ASST Rhodense, IBD Center- Gastroenterology Unit- Rho Hospital, Rho- Milan, Italy;(4)Fondazione Policlinico Universitario "A. Gemelli" IRCCS, CEMAD - IBD UNIT- Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italy;(5)Magna Graecia University, Department of Health Science, Catanzaro, Italy;(6)University of Messina, IBD-Unit- Department. of Clinical and Experimental Medicine, Messina, Italy;(7)Fondazione "Casa Sollievo della Sofferenza"- IRCCS, Department of Gastroenterology and Endoscopy, San Giovanni Rotondo, Italy;(8)San Filippo Neri Hospital, IBD Unit, Rome, Italy;(9)Azienda Ospedaliera-University of Padua, Inflammatory Bowel Disease Unit, Padua, Italy;(10)Campus Bio-Medico University, Gastroenterology Unit, Rome, Italy;(11)University of Cagliari, Department of Medical Science and Public Health- Gastroenterology Unit, Cagliari, Italy;(12)University of Milano-Bicocca, Gastroenterology Division ASST Monza Ospedale San Gerardo - Department of Medicine and Surgery, Monza, Italy;(13)University of Turin, Department of Medical Sciences, Turin, Italy;(14)Careggi University Hospital, Department of Gastroenterology, Florence, Italy;(15)IRCCS Humanitas Research Hospital, IBD Center, Rozzano- Milan, Italy;(16)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;
P456: Magnetic resonance enterography findings at week 46 after biological treatment predict long-term clinical outcomes in Crohn's disease patientsECCO’23 CopenhagenYear: 2023
Authors: Fernandez Clotet, A.(1)*;Ordás, I.(2);Masamunt, M.C.(3);Caballol, B.(3);Rodriguez, S.(4);Panés, J.(3);Ricart, E.(5);Rimola, J.(4);
(1)IBD Unit. Hospital Clinic de Barcelona, Gastroenterology, Barcelona, Spain;(2)IBD Unit. Hospital Clinic de Barcelona, Gastroenteroloy, Barcelona, Spain;(3)IBD Unit- Hospital Clinic de Barcelona, Gastroenterology, Barcelona, Spain;(4)IBD Unit- Hospital Clinic de Barcelona, Radiology, Barcelona, Spain;(5)IBD Unit- Hospital Clinic de Barcelona, Gasteroenterology, Barcelona, Spain;
P457: Treatment duration of ustekinumab in patients with Crohn's disease (CD) and psoriasis (PSO) – real-world evidence from German claims dataECCO’23 CopenhagenYear: 2023
Authors: Kosa, F.(1);Nair, S.(1);He, J.(1);Lin, X.(1);Di Scala, L.(1);Lehne, M.(2)*;Ghiani, M.(3);Maywald, U.(4);Wilke, T.(3);
(1)Janssen, Global Services LLC, Raritan NJ, United States;(2)Cytel, Real World Advanced Analytics, Berlin, Germany;(3)IPAM - Institut für Pharmakoökonomie und Arzneimittellogistik e.V., n/a, Wismar, Germany;(4)AOK Plus, Unternehmensbereich Versorgung, Dresden, Germany;
